Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer
NCT04109729Phase 1Active, not recruiting
- Sponsor
- University of Utah
- Start
- Sep 2020
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Utah. Primary endpoints: Frequency of grade 3 or greater non-hematologic treatment-emergent adverse events at 12 weeks and Circulating tumor DNA reduction at 14 weeks. Started Sep 2020; status: active, not recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04109729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109729.